

*B*loom Burton
Award *G*ala



Bloom Burton Award Gala Program
September 2017

Contents

2

WELCOME LETTER

Brian Bloom and Jolyon Burton

4

MESSAGE FROM THE MAYOR

John Tory

6

MESSAGE FROM THE PREMIER

Kathleen Wynne

8

MESSAGE FROM THE MINISTER OF INNOVATION, SCIENCE AND ECONOMIC DEVELOPMENT

Navdeep Bains

12

FINALIST PROFILES

Allen Eaves
Anthony Giovinazzo
Cameron Piron

18

JUDGING PANEL

Karen Bernstein
Terrence Connolly
Carl Gordon
Andrew Hack
Oleg Nodelman
Melinda Richter
Avik Roy





12

ALLEN EAVES

Founder, President and CEO
STEMCELL Technologies



14

ANTHONY GIOVINAZZO

Founder, Director, Inventor and CEO
Cynapsus Therapeutics



16

CAMERON PIRON

Founder and President
Synaptive Medical



Welcome

Thank you for attending the inaugural Bloom Burton Award Gala.

We are delighted that you are here to celebrate leaders in the Canadian healthcare sector.

The Bloom Burton Award Gala seeks to honour an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker – anyone - who has made the greatest impact in Canada’s innovative healthcare industry. It’s time to celebrate those who advance medical science, attract and provide risk capital, launch new products and companies on the world stage or announce significant monetization events.

The public-at-large nominated the candidates for this award and our international judging panel has narrowed and selected three finalists who deserve our recognition: Allan Eaves of STEMCELL Technologies, Anthony Giovinazzo of Cynapsus Therapeutics, and Cameron Piron of Synaptive Medical.

Let’s raise our glasses and toast their enormous achievements!

Brian, Jolyon and the Bloom Burton & Co. team



Evening Agenda

6:00 PM

Cocktail Reception

7:00 PM

Dinner

7:15 PM

Award Program

Welcome Remarks

Brian Bloom & Jolyon Burton

Keynote Address

Terrence Connolly
Celgene Corporation

Celebrating Allen Eaves

Celebrating Anthony Giovinazzo

Celebrating Cameron Piron

Winner Announced

9:00 PM

Dancing





“The city is proud of organizations and individuals that are committed to making a difference...”

John Tory
Mayor of Toronto



Message from the Mayor

It is my pleasure to extend greetings and a warm welcome to everyone attending the Bloom Burton Award Gala.

The City of Toronto is proud of organizations and individuals that are committed to making a difference and recognizes their contributions to the economic and social well-being of our communities. Their tremendous efforts and talents impact the lives of many and make our city better.

On behalf of Toronto City Council, I thank the organizers and wish everyone an informative and enjoyable event.

Yours truly,



John Tory
Mayor of Toronto



Premier of Ontario - Première ministre de l'Ontario

September 14, 2017

A PERSONAL MESSAGE FROM THE PREMIER

On behalf of the Government of Ontario, I am delighted to extend warm wishes to everyone attending the inaugural Bloom Burton Award Gala.

People are our most important resource. That is why caring for their health and well-being are of the utmost importance. Ensuring access to high quality universal health care is a priority for our government. As you know, Ontario's health care system faces increasing demands from an aging and growing population. Our government continues to move forward on transforming our health care system — to one that is patient-centred, efficient and integrated with other health and social services.

Our health care industry plays an important role in providing high quality health products and services to Ontarians. I thank Bloom Burton for hosting this gala and for its commitment to honouring and recognizing the most important contributor to the health care industry. I want to offer my congratulations to tonight's Bloom Burton award winner. Your achievements have helped make our health care industry stronger, more innovative and better able to respond to the challenges ahead of us.

Please accept my best wishes. Have a wonderful evening!

A handwritten signature in black ink that reads "Kathleen Wynne".

Kathleen Wynne
Premier



“Our health care industry plays an important role in providing high quality health products and services to Ontarians.”

Kathleen Wynne
Premier of Ontario



“Innovation starts with smart and creative people who find new solutions to difficult problems.”



Navdeep Bains
Minister of Innovation, Science
and Economic Development

Minister of
Innovation, Science and
Economic Development



Ministre de
l'Innovation, des Sciences et du
Développement économique

Ottawa, Canada K1A 0H5



**Message from the Honourable Navdeep Singh Bains,
Minister of Innovation, Science and Economic Development
Welcome Letter—Bloom Burton Award Gala**

On behalf of the Government of Canada, I am honoured to welcome participants to the Bloom Burton Award Gala.

I would also like to congratulate tonight's nominees and award recipients.

The life sciences and health care sectors are engines of knowledge and innovation. Your work has the potential to save lives as well as improve them. In the process, you create highly skilled well-paying jobs for Canadians.

That's how innovation makes a better Canada.

Innovation starts with smart and creative people who find new solutions to difficult problems.

That is why the Government of Canada has put forward the Innovation and Skills Plan. This plan will equip Canadians with the skills to adapt to a changing job market and prepare them for the jobs of today and the future.

This plan will make smart and responsible investments that will promote research excellence, open up new business opportunities and attract global investments that enable you to grow and compete beyond our borders.

I wish you great success as you continue to bring your discoveries from the lab to the clinic, where they can make a difference in the lives of Canadians.

Thank you for your contributions to a better Canada.

**Navdeep Bains
Minister of Innovation, Science
and Economic Development**

Canada 

Bloom Burton Award Gala

*T*he Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest impact in Canada's innovative healthcare industry. Nominees for the Award are accepted from the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, healthcare services or healthcare IT sectors, and from all therapeutic indications and stages of development.

The Bloom Burton Award winner is chosen by an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism.

The winner receives a \$50,000 cash prize, while the other two finalists each receive \$25,000.

*T*his year's finalists are: Allen Eaves, Anthony Giovinazzo and Cameron Piron



Bloom Burton & Co.

Bloom Burton & Co. exists to accelerate returns in healthcare

An important goal of all investors, companies and organizations is to achieve a monetizing event, such as the ability to raise capital, perform meaningful research and development, license or commercialize products, reach profitability or execute a strategic transaction.

The people who work at Bloom Burton have deep knowledge in medicine, science, patent and corporate law, finance and healthcare invention, development and commercialization.

The Bloom Burton team has been dedicated exclusively to the healthcare investment industry for more than a decade and, as a result of our deep expertise and experience, our clients achieve a faster path to their monetizing events.

Bloom Burton works with institutional and individual investors looking to invest in the healthcare sector. We also work with healthcare companies and organizations of all sizes and stages of development, who seek advice and capital.

As a result of our expertise and experience in healthcare, we have developed a disciplined methodology for helping companies grow faster. Our methodology, and all of the services we offer, rest on six key pillars: deeper due diligence, a broader range of investment options, greater understanding of cross-border rules, relationships with international healthcare-specialized investors, engagement with the broader healthcare community, and a creative, tenacious, entrepreneurial culture.

Our services help identify, cultivate and create investment opportunities in the healthcare sector, on behalf of companies and investors.

From start-ups to commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, life science tools, animal health, nutrition and wellness.

Our six business services work cohesively to accelerate monetization for both company and investor clients:



Raising Capital
& Financing



M&A
Advisory



Equity
Research



Monetization
Planning



Direct
Investment



Company
Creation





“We have this wonderful healthcare system but what we don’t do is produce a lot of the products that go into it.”



Allen Eaves

STEMCELL Technologies

Allen Eaves

Allen Eaves, OBC MD PhD FRCPC, was the Founding Director of the Terry Fox Laboratory for Cancer Research for 25 years (1981-2006) and Head of Clinical Hematology at the University of British Columbia for 18 years (1985-2003). Currently Professor Emeritus of Hematology at UBC since 2006, he has devoted himself to building STEMCELL Technologies Inc., a company he founded in 1993 to provide standardized tissue culture reagents for regenerative medicine and those doing cancer and immunological research. Always profitable and with only 3% of its sales in Canada, STEMCELL is now Canada's largest biotech company with over 1000 employees and a global network of sales offices and distribution centres serving thousands of customers.


Dr. Eaves has published over 200 papers in leading peer-review scientific journals. He has been elected as President of the International Society of Cell Therapy; President of the American Society of Blood and Marrow Transplantation; founding Treasurer of the Foundation for the Accreditation of Cell Therapy; and has been a Member of Health Canada's Expert Working Group on the Safety of Organs and Tissues for Transplantation. He sits on the boards of The Canadian Stem Cell Network, The Canadian Stem Cell Foundation, The Centre for Commercialization of Regenerative Medicine, and The Banff International Research Station for Mathematical Innovation and Discovery. He is passionate about providing excellent tools and reagents for researchers and creating rewarding employment for those who love science.

Anthony Giovinazzo

Anthony J. Giovinazzo has in excess of 38 years of professional experience. His first seven years were spent as an international corporate tax specialist primarily in multinational conglomerates. The subsequent eight years were spent in Fortune 100 investment banking and private equity. For the past 24 years he has been focussed solely on the discovery, development and commercialization of therapeutics for Alzheimer's, Parkinson's and neuropathic pain.

He is currently retired and is a Director on the Board of Promis Neurosciences Inc., a TSX listed company. From October 2016 to March 2017 he was President and CEO of Sunovion CNS Development Canada ULC., a successor company to Cynapsus Therapeutics Inc. Sunovion Pharmaceuticals Inc., a member of the Dainipon Sumitomo Pharma group of companies of Japan, purchased Cynapsus Therapeutics Inc. in the fall of 2016. Mr Giovinazzo was President, CEO and Director of Cynapsus Therapeutics Inc. from 2009 to 2016. During this period, he led the company in raising US \$136 million in private and public equity. He was one of the three original inventors and patent holders of the Cynapsus Parkinson's focussed technology. Under his leadership, the company successfully developed APL 130277 (a sublingual strip of apomorphine for OFF episodes) from Phase 1 to late stage Phase 3 studies. The potential approval of APL130277 (a reformulation of an already approved drug) could impact several millions of patients and their caregivers worldwide. Cynapsus Therapeutics Inc. graduated from the TSX-V to the TSX and eventually the NASDAQ, attracting tier 1 Wall St. investment banks and some of the largest institutional life science investors in the USA. The sale of Cynapsus resulted in a 120% premium to market price, an \$841 million all cash Canadian M&A transaction.

Mr Giovinazzo is the co-author of several peer reviewed papers and author of several papers on strategic and financing issues in the biopharmaceutical industry. During his career he was involved in several licensing and M&A transactions. In addition, he has raised over US \$750 million in private and public equity. He was a finalist in the EY Entrepreneur of the Year (2014) for Ontario, Canada. He is a Chartered Director and Audit Committee Certified, both from The Directors College, a degree granting affiliate of McMaster University. He completed the Leadership and Strategy in Pharmaceuticals and Biotech program in 2006 from Harvard Business School and received a Masters of Business Administration from IMD, Geneva Switzerland in 1986. He has a graduate certificate in Canadian Law from Osgoode Hall Law School (1984) and a Bachelor of Arts in Economics and Accounting from McMaster University (1978).



“You can invent things here in Canada and you can develop them here in Canada, and you can actually generate real value for them.”

Anthony Giovinazzo
Cynapsus Therapeutics



“I think Canada can become less known as a natural resource economy and more known as a hi-tech contributor to the world.”

Cameron Piron
Synaptive Medical

Cameron Piron

Cameron Piron is an industry-recognized leader and innovator in image-guided surgery. Prior to co-founding Synaptive Medical, Cameron was president and co-founder of Sentinelle Medical, a medical device company that developed and manufactured advanced MRI-based breast imaging technologies. Sentinelle grew to over 200 employees and over \$20 million in revenues before being acquired by Hologic, Inc. in 2010. Cameron studied systems design engineering at the University of Waterloo, followed by a graduate degree at the University of Toronto in medical biophysics. His awards include the Ontario Premier's Catalyst Award for Best Young Innovator in 2008; the University of Waterloo's Alumni Achievement medal in 2009 for leading Sentinelle Medical in researching and manufacturing leading edge MRI technologies that allow physicians to diagnose breast cancer and other medical conditions faster and more accurately; being named to Canada's Top 40 Under 40™ list in 2009, which was established by Caldwell Partners and celebrates the achievements of young Canadians in the private, public and non-profit sectors; and being the first Canadian ever to win R&D Magazine's Innovator of the Year award in 2008. In 2015, Cameron was named one of Fast Company's Most Creative People. He chairs Synaptive's Board of Directors and heads the company's executive committee.

Judging Panel



Karen Bernstein has been writing and publishing on biotechnology since 1987. From the inception of BioCentury in 1992 until she stepped down in September 2015, she was also Editor-in-Chief. She sits on the board of Ovid Therapeutics Inc. and was a board member at Vitae Pharmaceuticals Inc. until its acquisition last year by Allergan plc. She is a trustee at the Keck Graduate Institute and a member of the board of advisors of KGI's School of Pharmacy.

In 2016, she was named Mediscience Commentator of the Year at the European Mediscience Awards. In 2015, Scientific American named Karen one of The WorldVIEW 100 most influential people in biotech today. In 2013, she was named one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal. In 2007, Karen received a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2005, the annual gathering of biotechnology chief executive officers at The Biotech Meeting in Laguna Niguel, Calif., inducted Karen into their Hall of Fame, citing her lifetime contribution to the biotech community.

She received a Ph.D. in political science from Stanford University in 1983. She graduated magna cum laude with a B.A. in politics and history from Brandeis University in 1974.



Terrence (Terry) Connolly, Ph.D., is an Executive Director of Business Development for US-based biopharmaceutical company Celgene Corporation, where he is a member of a team responsible for leading all activities related to global transactions. Prior to this current role, he worked in Celgene's Alliance Management group where he was the primary Celgene touch point for assigned strategic corporate alliances partners. Terry started his industrial career as a process chemist for Raylo Chemicals, and had a number of positions with increasing responsibilities in the field of chemical development for Roche, Wyeth and Celgene. Terry received a Ph.D. in Organic Chemistry from the University of Ottawa (1996) and a Bachelor of Science Degree with Honors in Chemistry from Mount Allison University (1991).



Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987). Carl was included on the Forbes Midas List of top venture capital investors in 2014.



Andrew A. F. Hack, M.D., Ph.D., has served as the Chief Financial Officer of Editas Medicine since July 2015. Prior to joining Editas, from May 2011 to June 2015, Dr. Hack was a portfolio manager at Millennium Management LLC, an institutional asset manager, where he ran a healthcare fund focused on biotechnology, pharmaceutical, and medical device companies. Before joining Millennium Management, Dr. Hack was a healthcare analyst at HealthCor Management, L.P., a registered investment advisor, from December 2008 to May 2011. Prior to HealthCor, he served as a healthcare analyst for hedge fund Carlyle-Blue Wave Partners and as principal of the MPM BioEquities Fund, a hedge fund that was affiliated with MPM Capital. Dr. Hack began his investment career covering the biotechnology sector at investment banks Banc of America Securities LLC and Rodman & Renshaw, LLC. He co-founded Reify Corporation, a life science tools and drug discovery company. Dr. Hack serves as a director of Mersana Therapeutics, Inc., a private company. He received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D.



Oleg Nodelman is the Founder and Managing Director of EcoR1 Capital Fund, a leading biotech focused investment fund. With 16 years of experience in investing and consulting, Mr. Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Mr. Nodelman was a Portfolio Manager at BVF Partners, one of biotech's first dedicated hedge funds. During his 11 years with BVF, Mr. Nodelman's responsibilities spanned the entire investment process, from opportunity generation and due diligence to portfolio management and trading. Mr. Nodelman began his career in strategic consulting and organizational management at Mercer Management Consulting (now Oliver Wyman), where he worked with senior management from companies in a variety of industries to develop and implement long-term strategy and build shareholder value. Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.



Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson's sectors: consumer, medical device and pharmaceuticals.

Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS' operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France.

Melinda has received numerous industry awards including: the PharmaVOICE 100; Fierce Biotech Top 15 Women; Most Influential Women in Business (San Francisco Business Times); MM&M 2017 Healthcare Transformer; BIO Super Hero; and FastCompany Most Innovative Company in Biotech.

Melinda is an active board member and Treasurer of the California Life Sciences Association (CLSA), a board member of BIO's Technology Transfer Committee, the Texas Health Catalyst Advisory Panel (The Dell Medical School and the Provost office of the University of Texas at Austin), the University of Toronto & Janssen Neuroscience Catalyst, A*STAR ETPL's Strategic Advisory Panel.



Avik Roy is one of North America's leading experts on healthcare policy. His reform proposal, *Transcending Obamacare: A Patient-Centered Plan for Near-Universal Coverage and Permanent Fiscal Solvency*, is one of the plans most influential in Washington as Republicans debate how to replace the Affordable Care Act.

Mr. Roy advised a number of the 2016 presidential candidates on healthcare and other areas of public policy, including Marco Rubio and Rick Perry. In 2012, Mr. Roy served as healthcare policy advisor to Mitt Romney; in that role, he helped develop Romney's agenda on healthcare and entitlement reform for the 2012 presidential campaign. He also served on Romney's presidential transition team, in which capacity he was responsible for recommending candidates for the major healthcare positions in the federal government, including at HHS, CMS, and the FDA.

Mr. Roy is the President of the Foundation for Research on Equal Opportunity (FREOPP.org) and the Managing Partner at Roy Healthcare Research, LLC, which provides proprietary healthcare investment and policy research to institutional investors and stakeholders. Roy's work has been praised widely on both the right and the left. *National Review* has called him one of America's "sharpest policy minds," while the *New York Times'* Paul Krugman described him as man of "personal and moral courage."

Prior to his career in healthcare policy, Mr. Roy spent a dozen years on the Wall Street buy side as a health care analyst and portfolio manager at institutions such as Bain Capital and J.P. Morgan.

Bloom Burton Award Gala

Our sincere gratitude to all who helped make this evening a success:

- Our three finalists
- Our judges
- Our table sponsors
- Bloom Burton & Co. staff
- The Four Seasons Hotel
- Sole Power Productions





DEC 6th 2017

HOLIDAY PARTY

BYMARK
66 Wellington Street W
Toronto, ON M5K 1M6
5:30-9:30PM

A network diagram background consisting of numerous interconnected nodes of varying sizes and colors (white, grey, blue, orange) connected by thin lines, set against a dark gradient background.

Bloom Burton & Co. Healthcare Investor Conference

May 2 - May 3, 2018

Sheraton Centre Hotel Toronto

123 Queen Street W
Toronto, ON M5H 2M9



bloom burton & co

/accelerating returns in healthcare

Table Sponsors

Thank you to our table sponsors:



Wilson Sonsini Goodrich & Rosati
PROFESSIONAL CORPORATION

Thank you to our block ticket sponsors:



